Core Viewpoint - The discussion at the "Innovative Progress in Cancer Treatment and New Trends in Drug Development Forum" highlighted the importance of addressing unmet medical needs in women's health, particularly in cervical cancer prevention and treatment [1] Company Summary - Aihong Pharmaceutical is focused on transforming the treatment of cervical precancerous lesions from invasive surgery to non-invasive, fertility-friendly methods [1] - The company's product APL-1702 has entered the second round of technical review by the CDE, indicating that it is in the final stages of preparation for market launch [1] - Aihong Pharmaceutical emphasizes its commitment to continuous innovation in women's health and aims to expedite the approval, access, and application of APL-1702 in the Chinese market [1]